APA

Fenton R. T., Sznol M., Luster D. G., Taub D. D. & Longo D. L. (19950505). A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. : Human gene therapy.

Chicago

Fenton R T, Sznol M, Luster D G, Taub D D and Longo D L. 19950505. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. : Human gene therapy.

Harvard

Fenton R. T., Sznol M., Luster D. G., Taub D. D. and Longo D. L. (19950505). A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. : Human gene therapy.

MLA

Fenton R T, Sznol M, Luster D G, Taub D D and Longo D L. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. : Human gene therapy. 19950505.